- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
Hypertension In Autosomal Dominant Polycystic Kidney Disease (ADPKD), Chronic Kidney Disease (CKD), & The General Population
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Hypertension In Autosomal Dominant Polycystic Kidney Disease (ADPKD), Chronic Kidney Disease (CKD), & The General Population
Background
Hypertension (HTN) is the first complication of ADPKD in 30% of patients and it is more common among men than women. Approximately 20% of patients <20 years old have HTN. Earlier onset of HTN is more common with PKD1 mutation compared to PKD2 and also if a parent with ADPKD has HTN.1,2 Hypertensive patients with ADPKD and preserved kidney function have greater total kidney volume (TKV), higher proteinuria, and decreased renal blood flow than normotensive patients with ADPKD.2 The mechanism is incompletely understood and there are similarities and differences in the pathophysiology and management of HTN in patients with ADPKD, CKD, and the general population (GP).Did You Know?
- Hypertension precedes kidney function loss in >60% of patients with ADPKD.2
Why Attend This Webinar?
- Dr. Workeneh, a double Board-certified nephrologist and internist, and professor will discuss the pathophysiology and management of HTN in patients with ADPKD, CKD, and the GP.
What You Will Learn
1. The pathophysiology of ADPKD and HTN 2. The pathophysiology of HTN in the GP versus patients with ADPKD and CKD 3. The management of HTN in the GP, in patients with ADPKD, and CKDReferences
1. Rahbari-Oskoui F, Williams O, Chapman A. Nephrology Dialysis Transplantation. 2014;29(12):2194-2201. 2. Chapman AB, Stepniakowski K, Rahbari-Oskoui F. Adv Chronic Kidney Dis. 2010;17(2):153-163.Featuring
Biruh T Workeneh, MD, FASN
Associate Professor, Department of Emergency Medicine, Division of Internal MedicineThe University of Texas MD Anderson Cancer Center*
Dr Biruh Workeneh is a provider in the MD Anderson Internal Medicine Center and an Associate Professor in the Section of Nephrology. He is board-certified in Internal Medicine and joined MD Anderson in 2015.
Moderator
Rim Hadgu, PharmD, BCPS
Nephrology Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Dr Rim Hadgu is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization. She obtained her Doctor of Pharmacy degree from St. Louis College of Pharmacy. She completed an American Society of Health-System Pharmacists (ASHP)-Accredited PGY1 Pharmacy Residency at Xavier University of Louisiana College of Pharmacy and University Medical Center New Orleans. She also completed an ASHP-Accredited PGY2 Nephrology Pharmacy Residency at Albany College of Pharmacy and Health Sciences. Prior to joining Otsuka in October 2021, she was an Assistant Professor of Pharmacy Practice at Midwestern University College of Pharmacy, Glendale Campus where she delivered lectures, precepted Advanced Pharmacy Practice Experience students as well as PGY1 and PGY2 pharmacy residents. She also practiced as a nephrology clinical pharmacist for two years. Dr Hadgu is a Board Certified Pharmacotherapy Specialist by the Board of Pharmacy Specialties.
Jessica Kanai, PharmD
Nephrology Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Jessica Kanai PharmD, is a Nephrology Medical Science Liaison at Otsuka. Dr Kanai obtained her PharmD from Duquesne University in Pittsburgh, Pennsylvania. She completed her PGY-1 residency at Memorial Health University Medical Center in Savannah, Georgia where she stayed on and worked in both emergency medicine and internal medicine. She was responsible for a diverse patient population including those with end stage renal disease. Dr Kanai then went on to obtain her Australian pharmacy license and worked with numerous specialty services at the Royal Hobart Hospital such as neurosurgery, cardiology and pulmonology. Upon returning to the states, she became the nephrology pharmacist at WVU Medicine and was also involved in initiating pharmacy rounding services with WVU Medicine’s cardiology specialty. Dr Kanai is currently a licensed pharmacist in Pennsylvania and West Virginia.
*Dr Biruh Workeneh is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Drs Rim Hadgu & Jessica Kanai are employees of OPDC.
Registration
Related Events
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
